A study published April 17 by BMC Infectious Diseases found increased incidents of Acinetobacter baumannii and ...

The following is a summary of “Clinical burden of Acinetobacter baumannii, including carbapenem-resistant A. baumannii, in ...

The clinical burden of carbapenem-resistant Acinetobacter baumannii has worsened across U.S. hospitals in recent years, according to a study published April 17 in BMC Infectious Diseases.  The ...

The finding, therefore, of an innovative antibacterial compound — one that has in vivo activity against a clinically relevant target (the bacterium Acinetobacter baumannii) — should rightly be ...

Experts say there is limited information on the superbug which has been described as a 'significant risk to public health' ...

Acinetobacter baumannii has emerged in the last decades as a major cause of healthcare-associated infections and nosocomial outbreaks. Multidrug-resistant (MDR) A. baumannii is a rapidly emerging ...

The antibiotic-resistant ‘superbug' causes severe disease and poses significant challenges to global public health ...

Co. Ltd. has identified cyclopeptides reported to be useful for the treatment of Acinetobacter infections, particularly A. baumannii infections.

Drug-resistant bacteria such as Acinetobacter baumannii, which causes life-threatening infections in people with a weakened immune system, and Pseudomonas aeruginosa, linked to chronic lung ...

The genomic epidemiology of Acinetobacter baumannii, which is rising in virulence and multidrug resistance, was explored. This study examined bloodstream infection isolates from Chinese patients ...

The conference will feature an oral presentation of the BV100 Phase 2 data in patients with ventilator associated bacterial pneumonia (VABP) suspected or confirmed to be due to carbapenem resistant ...